You will be provided with a reference and some statements. Please determine whether each statement is 'supported', 'unsupported', or 'unknown' with respect to the reference. Please note:
First, assess whether the reference contains any valid content. If the reference contains no valid information, such as a 'page not found' message, then all statements should be considered 'unknown'.
If the reference is valid, for a given statement: if the facts or data it contains can be found entirely or partially within the reference, it is considered 'supported' (data accepts rounding); if all facts and data in the statement cannot be found in the reference, it is considered 'unsupported'.

You should return the result in a JSON list format, where each item in the list contains the statement's index and the judgment result, for example:
[
    {
        "idx": 1,
        "result": "supported"
    },
    {
        "idx": 2,
        "result": "unsupported"
    }
]

Below are the reference and statements:
<reference>
2023 Focused Update of ESC Guidelines for Acute and Chronic HF: Key Points - American College of Cardiology

Debabrata Mukherjee, MD, FACC

ACC

ACC.27-WCC

JACC

Accreditation

NCDR

Cardiosmart

MedAxiom

Create Account

Log In

Become a Member

Guidelines

DocMatter

Contact Us

Donate

Menu

Log In

About ACC

Leadership & Governance

Membership

Benefits of Your Membership

Leadership & Professional Development

Member Sections

Global Hub

Become a Member

The ACC Foundation

Advocacy

Health Equity

Innovation

Contact Us

Latest In Cardiology

News

Cardiology Magazine

Guidelines & Clinical Policy

Podcasts

Education & Meetings

Online Learning Catalog

Products

ACC Anywhere: The Cardiology Video Library

SAPs: Self-Assessment Programs

Cardiac CT

ECG Drill and Practice

Heart Songs

Nuclear Cardiology

Institutional Products

CardioSource® Plus

Leadership & Professional Development

Certificates-and-Certifications

CCKE

NP/PA-CCKE

ACC Peer Review Certificate Program

Collaborative Maintenance Pathway

Understanding MOC

Educational Catalog PDF

Meetings

Webinar - Live

Webinars - On Demand

Annual Scientific Session

Solutions & Tools

Advocacy at the ACC

Career Solutions

Clinician Well-Being

Cardiology as a Career Path

Cardiology Careers: Job Board

Clinical Solutions

Clinical Solutions for Everyday Practice

Coding & Physician Reimbursement

Infographics

Institutional Solutions

Educational Products

Equipment Buyers Guide

AI Resources

Mobile and Web Apps

Clinical Topics

Acute Coronary Syndromes

Anticoagulation Management

Arrhythmias and Clinical EP

Cardiac Surgery

Cardio-Oncology

Cardiovascular Care Team

Congenital Heart Disease and Pediatric Cardiology

COVID-19 Hub

Diabetes and Cardiometabolic Disease

Dyslipidemia

Geriatric Cardiology

Heart Failure and Cardiomyopathies

Invasive Cardiovascular Angiography and Intervention

Noninvasive Imaging

Pericardial Disease

Prevention

Pulmonary Hypertension and Venous Thromboembolism

Sports and Exercise Cardiology

Stable Ischemic Heart Disease

Valvular Heart Disease

Vascular Medicine

Become a Member

Guidelines

DocMatter

Contact Us

Donate

ACC

ACC.27-WCC

JACC

Accreditation

NCDR

Cardiosmart

MedAxiom

Create Account

< Back to Listings

2023 Focused Update of ESC Guidelines for Acute and Chronic HF: Key Points

Aug 29, 2023

|
Debabrata Mukherjee, MD, FACC

Print

Font Size

A

A

A

Authors:

McDonagh TA, Metra M, Adamo M, et al., on behalf of the ESC Scientific Document Group.

Citation:

2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) With the Special Contribution of the Heart Failure Association (HFA) of the ESC.
Eur Heart J
2023;Aug 25:[Epub ahead of print].

The following are key points to remember from the 2023 Focused Update of the 2021 European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure:

This 2023 Focused Update addresses changes in recommendations for the treatment of heart failure (HF) because of availability of new evidence.

A sodium–glucose co-transporter 2 (SGLT2) inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HF with mildly reduced ejection fraction (HFmrEF) to reduce the risk of HF hospitalization or cardiovascular (CV) death (Class I, level of evidence [LOE] A).

An SGLT2 inhibitor (dapagliflozin or empagliflozin) is recommended in patients with HF with preserved EF (HFpEF) to reduce the risk of HF hospitalization or CV death (Class I, LOE A).

An intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge and during frequent and careful follow-up visits in the first 6 weeks following an HF hospitalization is recommended to reduce the risk of HF rehospitalization or death (Class I, LOE B).

In patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), SGLT2 inhibitors (dapagliflozin or empagliflozin) are recommended to reduce the risk of HF hospitalization or CV death (Class I, LOE A).

In patients with T2DM and CKD, finerenone is recommended to reduce the risk of HF hospitalization (Class I, LOE A).

Intravenous iron supplementation is recommended in symptomatic patients with HF with reduced EF (HFrEF) and HFmrEF, and iron deficiency, to alleviate HF symptoms and improve quality of life (Class I, LOE A).

Intravenous iron supplementation with ferric carboxymaltose or ferric derisomaltose should be considered in symptomatic patients with HFrEF and HFmrEF, and iron deficiency, to reduce the risk of HF hospitalization (Class IIA, LOE A).

Clinical Topics:

Heart Failure and Cardiomyopathies,
Prevention,
Acute Heart Failure

Keywords:

Acute Heart Failure,
Anemia, Iron-Deficiency,
Diabetes Mellitus, Type 2,
ESC Congress,
ESC23,
Heart Failure,
Patient Discharge,
Patient Readmission,
Quality of Life,
Renal Insufficiency, Chronic,
Secondary Prevention,
Sodium-Glucose Transporter 2 Inhibitors,
Stroke Volume

< Back to Listings

x

You must be
logged in
to save to your library.

Close

Related Content

New ESC Guidelines Address ACS, Cardiomyopathies, Diabetes, Endocarditis and HF

Similar Articles from ACC.org

Sep 15, 2026

|

ACC News Story

CMS Releases Final Ambulatory Specialty Model Participant List For 2027

Sep 10, 2026

|

Journal Scan

Look AHEAD: IL-6, Not hs-CRP, Identifies Risk of HF in Patients With T2D, Overweight/Obesity

Sep 09, 2026

|

Podcast

Eagle’s Eye View: Top Trials from ESC 26

Sep 02, 2026

|

Podcast

Eagle’s Eye View: M-TEER Improves MR and LV Dysfunction

Sep 01, 2026

|

Cardiology Magazine

New in Clinical Guidance | Antiplatelets in ASCVD; DOACs in Preventing Thrombotic Events; Global HF Definition

< Back to Listings

YOU ARE HERE:

Home
>

Latest in Cardiology
>
2023 Focused Update of ESC Guidelines for Acute and Chronic HF: Key Points

About ACC

Leadership & Governance

The ACC Foundation

Advocacy

Health Equity

Innovation Program

Jobs at the ACC

Our Bylaws and Code of Ethics

Industry Relations

Book Our Conference Center

Membership

Become a Member

Renew Your Membership

Benefits of Your Membership

Member Sections

Chapters

Global Hub

ACC Member Directory

Donate Today

Latest In Cardiology

News

Cardiology Magazine

Guidelines & Clinical Policy

Podcasts

Education & Meetings

Online Learning Catalog

Products & Resources

ACC Anywhere: The Cardiology Video Library

SAPs: Self-Assessment Programs

CardioSource® Plus

Certificates & Certifications

Leadership & Professional Development

Collaborative Maintenance Pathway

Understanding MOC

Meetings

Annual Scientific Session

Solutions & Tools

Clinician Well-Being

Cardiology as a Career Path

Cardiology Careers: Job Board

Practice Solutions

Clinical Solutions for Everyday Practice

Infographics

Educational Products

Equipment Buyers Guide

AI Resources

Mobile and Web Apps

Clinical Topics

JACC Journals on ACC.org

JACC

JACC: Advances

JACC: Asia

JACC: Basic to Translational Science

JACC: CardioOncology

JACC: Cardiovascular Imaging

JACC: Cardiovascular Interventions

JACC: Case Reports

JACC: Clinical Electrophysiology

JACC: Heart Failure

JACC

NCDR

Accreditation Services

CardioSmart

MedAxiom

Contact Us

Heart House

2400 N St. NW

Washington
,

DC

20037

Contact Member Care

Phone:

1-202-375-6000

Toll Free:

1-800-253-4636

Fax:

1-202-375-6842

Media Center

Advertise With Us

Advertising & Sponsorship Policy

Press Releases

Social Media

About UX

Clinical Content Disclaimer

ACC.org Editorial Reviewers

Annual Report

Privacy Policy

Registered User Agreement

Terms of Service

Cookie Policy

Site Map

Cookie Settings

© 2026 American College of Cardiology Foundation. All rights reserved.
</reference>

<statements>
1. IV iron Class I (Level A) to improve symptoms/QoL; Class IIa (Level A) to reduce HF hospitalization in symptomatic HFrEF/HFmrEF with iron deficiency (defined as ferritin <100 ng/mL, or 100–299 with TSAT <20%).
</statements>

Begin the assessment now. Output only the JSON list, without any conversational text or explanations.